Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder

Alcohol

Volumn 49, Issue 6, 2015, Pages 553-559

  Yardley, Megan M ^a   Huynh, Nhat ^b   Rodgers, Kathleen E ^b   Alkana, Ronald L ^b   Davies, Daryl L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alcoholism therapy; Drug delivery; Drug repositioning; Medications development

Indexed keywords

IVERMECTIN; PLACEBO;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALORIC INTAKE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SOLUBILITY; FAT INTAKE; FEMALE; FLUID INTAKE; HISTOLOGY; MOUSE; NONHUMAN; ORGAN WEIGHT; TREATMENT DURATION; WEIGHT CHANGE; ALCOHOL-RELATED DISORDERS; ANIMAL; C57BL MOUSE; DRINKING BEHAVIOR; DRUG DELIVERY SYSTEM; DRUG REPOSITIONING; ORAL DRUG ADMINISTRATION; PATHOLOGY; PROCEDURES; PSYCHOLOGY; SOLUBILITY;

ANIMALIA; MUS;

ADMINISTRATION, ORAL; ALCOHOL DRINKING; ALCOHOL-RELATED DISORDERS; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG REPOSITIONING; FEMALE; IVERMECTIN; MICE; MICE, INBRED C57BL; SOLUBILITY;

EID: 84940448630     PISSN: 07418329     EISSN: 18736823     Source Type: Journal    
DOI: 10.1016/j.alcohol.2015.03.006     Document Type: Article

References (42)

1. Asatryan L., Popova M., Perkins D., Trudell J.R., Alkana R.L., Davies D.L. Ivermectin antagonizes ethanol inhibition in purinergic P2X4 receptors. The Journal of Pharmacology and Experimental Therapeutics 2010, 334:720-728.
2. Asatryan L., Yardley M.M., Khoja S., Trudell J.R., Hyunh N., Louie S.G., et al. Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders. The International Journal of Neuropsychopharmacology 2014, 17:907-916.
3. Bala R., Pawar P., Khanna S., Arora S. Orally dissolving strips: a new approach to oral drug delivery system. International Journal of Pharmaceutical Investigation 2013, 3:67-76.
4. Bortolato M., Yardley M.M., Khoja S., Godar S.C., Asatryan L., Finn D.A., et al. Pharmacological insights into the role of P2X4 receptors in behavioural regulation: lessons from ivermectin. The International Journal of Neuropsychopharmacology 2013, 16:1059-1070.
5. Bouchery E.E., Harwood H.J., Sacks J.J., Simon C.J., Brewer R.D. Economic costs of excessive alcohol consumption in the U.S., 2006. American Journal of Preventive Medicine 2011, 41:516-524.
6. Brown A.P., Dinger N., Levine B.S. Stress produced by gavage administration in the rat. Contemporary Topics in Laboratory Animal Science 2000, 39:17-21.
7. Chatterjee S., Bartlett S.E. Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders. CNS & Neurological Disorders Drug Targets 2010, 9:60-76.
8. Cully D.F., Vassilatis D.K., Liu K.K., Paress P.S., Van der Ploeg L.H., Schaeffer J.M., et al. Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 1994, 371:707-711.
9. Currie B.J., Harumal P., McKinnon M., Walton S.F. First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clinical Infectious Disease 2004, 39:e8-12.
10. Dent J.A., Davis M.W., Avery L. avr-15 encodes a chloride channel subunit that mediates inhibitory glutamatergic neurotransmission and ivermectin sensitivity in Caenorhabditis elegans. The EMBO Journal 1997, 16:5867-5879.
11. Edlund M.J., Booth B.M., Han X. Who seeks care where? Utilization of mental health and substance use disorder treatment in two national samples of individuals with alcohol use disorders. Journal of Studies on Alcohol and Drugs 2012, 73:635-646.
12. Froehlich J.C., Hausauer B.J., Federoff D.L., Fischer S.M., Rasmussen D.D. Prazosin reduces alcohol drinking throughout prolonged treatment and blocks the initiation of drinking in rats selectively bred for high alcohol intake. Alcoholism: Clinical and Experimental Research 2013, 37:1552-1560.
13. Fuller R.K., Hiller-Sturmhöfel S. Alcoholism treatment in the United States. An overview. Alcohol Research & Health 1999, 23:69-77.
14. Geary T.G. Ivermectin 20 years on: maturation of a wonder drug. Trends in Parasitology 2005, 21:530-532.
15. Germann P.G., Ockert D. Granulomatous inflammation of the oropharyngeal cavity as a possible cause for unexpected high mortality in a Fischer 344 rat carcinogenicity study. Laboratory Animal Science 1994, 44:338-343.
16. Ghodake P.P., Karande K.M., Osmani R.A., Bhosale R.R., Harkare B.R., Kale B.B. Mouth dissolving films: innovative vehicle for oral drug delivery. International Journal of Pharma Research & Review 2013, 2:41-47.
17. Grant B.F., Dawson D.A., Stinson F.S., Chou S.P., Dufour M.C., Pickering R.P. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991-1992 and 2001-2002. Drug and Alcohol Dependence 2004, 74:223-234.
18. Harwood H. Updating estimates of the economic costs of alcohol abuse in the United States: Estimates, update methods, and data 2000, NIAAA Newsletter. http://pubs.niaaa.nih.gov/publications/economic-2000/alcoholcost.PDF.
19. Hendrickson L.M., Guildford M.J., Tapper A.R. Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence. Frontiers in Psychiatry 2013, 4:29.
20. Hoggatt A.F., Hoggatt J., Honerlaw M., Pelus L.M. A spoonful of sugar helps the medicine go down: a novel technique to improve oral gavage in mice. Journal of the American Association for Laboratory Animal Science 2010, 49:329-334.
21. Jelinková I., Yan Z., Liang Z., Moonat S., Teisinger J., Stojilkovic S.S., et al. Identification of P2X4 receptor-specific residues contributing to the ivermectin effects on channel deactivation. Biochemical and Biophysical Research Communications 2006, 349:619-625.
22. Johnson B.A. Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochemical Pharmacology 2008, 75:34-56.
23. Khakh B.S., Proctor W.R., Dunwiddie T.V., Labarca C., Lester H.A. Allosteric control of gating and kinetics at P2X(4) receptor channels. The Journal of Neuroscience 1999, 19:7289-7299.
24. Kosten T.A. Pharmacologically targeting the P2rx4 gene on maintenance and reinstatement of alcohol self-administration in rats. Pharmacology, Biochemistry, and Behavior 2011, 98:533-538.
25. Krause R.M., Buisson B., Bertrand S., Corringer P.J., Galzi J.L., Changeux J.P., et al. Ivermectin: a positive allosteric effector of the alpha7 neuronal nicotinic acetylcholine receptor. Molecular Pharmacology 1998, 53:283-294.
26. Mandeep K., Rana A.C., Nimrata S. Fast dissolving films: an innovative drug delivery system. International Journal of Pharmaceutical Research and Allied Sciences 2013, 2:14-24.
27. Miller P.M., Book S.W., Stewart S.H. Medical treatment of alcohol dependence: a systematic review. International Journal of Psychiatry in Medicine 2011, 42:227-266.
28. Molinari G., Soloneski S., Larramendy M.L. New ventures in the genotoxic and cytotoxic effects of macrocyclic lactones, abamectin and ivermectin. Cytogenetic and Genome Research 2010, 128:37-45.
29. Panda B.P., Dey N.S., Rao M.E.B. Development of innovative orally fast disintegrating film dosage forms: a review. International Journal of Pharmaceutical Sciences and Nanotechnology 2012, 5:1666-1674.
30. Impact of alcoholism and alcohol induced disease on America 2011, Research Society on Alcoholism, from:. http://www.rsoa.org/2011-04-11RSAWhitePaper.pdf.
31. Richard-Lenoble D., Chandenier J., Gaxotte P. Ivermectin and filariasis. Fundamental & Clinical Pharmacology 2003, 17:199-203.
32. Saini P., Kumar A., Sharma P., Visht S. Fast disintegrating oral films: a recent trend of drug delivery. International Journal of Drug Development and Research 2012, 4:80-94.
33. Sattelle D.B., Buckingham S.D., Akamatsu M., Matsuda K., Pienaar I.S., Jones A.K., et al. Comparative pharmacology and computational modelling yield insights into allosteric modulation of human alpha7 nicotinic acetylcholine receptors. Biochemical Pharmacology 2009, 78:836-843.
34. Silberberg S.D., Li M., Swartz K.J. Ivermectin interaction with transmembrane helices reveals widespread rearrangements during opening of P2X receptor channels. Neuron 2007, 54:263-274.
35. Silverman J.L., Oliver C.F., Karras M.N., Gastrell P.T., Crawley J.N. AMPAKINE enhancement of social interaction in the BTBR mouse model of autism. Neuropharmacology 2013, 64:268-282.
36. Sung Y.F., Huang C.T., Fan C.K., Lin C.H., Lin S.P. Avermectin intoxication with coma, myoclonus, and polyneuropathy. Clinical Toxicology (Philadelphia, PA) 2009, 47:686-688.
37. Vassilatis D.K., Arena J.P., Plasterk R.H., Wilkinson H.A., Schaeffer J.M., Cully D.F., et al. Genetic and biochemical evidence for a novel avermectin-sensitive chloride channel in Caenorhabditis elegans: Isolation and characterization. The Journal of Biological Chemistry 1997, 272:33167-33174.
38. Global status report on alcohol and health 2011, 1-286. World Health Organization.
39. Wyatt L.R., Finn D.A., Khoja S., Yardley M.M., Asatryan L., Alkana R.L., et al. Contribution of P2X4 receptors to ethanol intake in male C57BL/6 mice. Neurochemical Research 2014, 3:1127-1139.
40. Yardley M.M., Neely M., Huynh N., Asatryan L., Louie S.G., Alkana R.L., et al. Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans. Neuroreport 2014, 25:1018-1023.
41. Yardley M., Wyatt L., Khoja S., Asatryan L., Ramaker M.J., Finn D.A., et al. Ivermectin reduces alcohol intake and preference in mice. Neuropharmacology 2012, 63:190-201.
42. Zhang L. Voluntary oral administration of drugs in mice 2011, Protocol Exchange. http://www.nature.com/protocolexchange/protocols/2099.